Mp50-05 Identifying Practice Patterns for Thromboprophylaxis After Radical Cystectomy.

VanDlac, Amanda; Cowan, Nicholas; Chen, Yiyi; Rochelle, Jeffery La; Amling, Christopher; Koppie, Theresa M.

doi:10.1016/j.juro.2014.02.1126

“…There are many possible explanations for the large variations in the rates of VTE observed within this group: for example, the heterogeneity of risk factors in this population that could affect the rate of VTE such as minimal invasive (robotic) cystectomy or open radical cystectomy [10]. Additionally, 33 of the included studies did not state, discuss or categorise BC patients according to confounding factors that alter the rate of VTE such as receiving surgical thromboprophylaxis for 14 or 28 days, which then makes it difficult to compare rates between studies [13,[15][16][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53]. All included studies, with the exception of two [19][20], did not clearly discuss or state the thromboprophylaxis measures employed.…”

Section: Discussion Of the Systematic Reviewmentioning

confidence: 99%

Venous Thromboembolism Rate in Patients With Bladder Cancer According to the Type of Treatment: A Systematic Review

Abdullah¹,

Parashar²,

Mustafa³

et al. 2022

Cureus

View full text Add to dashboard Cite

Bladder cancer (BC) is classified as a high-risk tumour type for venous thromboembolism (VTE). VTE presents an extra challenge in the management of patients with cancer, given the increase in morbidity and mortality on having both conditions.To summarise the contemporary evidence on the VTE rate in patients with BC according to the stage, type of anti-cancer treatment and highlight VTE rate in the UK and other countries. A systematic review was carried out, and an electronic search for publications between January 2000 and November 2021 was done. Studies recording VTE in BC patients were included, whilst paediatric patients, case reports, studies reporting on a mix of arterial and venous thrombosis, studies reporting DVT or PE only and recorded hospitalised VTE only were excluded. The rate of VTE, country of origin, risk factors and thromboprophylaxis duration for VTE in BC patients were identified.A total of 38 papers met the search criteria. All publications were original research papers (cohort studies). The overall VTE rate in patients with BC was estimated at 1.9% to 4.7%. For those patients undergoing cystectomy, the VTE rate ranged from 3% to 17.6%; however, the VTE rate in the metastatic stage of BC patients ranged from 3.1% to 5.1%.The rates of VTE in BC patients are high, further increased by interventions such as surgery and chemotherapy. Thromboprophylaxis measures should be optimised. This review highlighted the fact that the VTE rate in BC varies between studies due to the heterogeneity of risk factors reported.

show abstract

“…There are many possible explanations for the large variations in the rates of VTE observed within this group: for example, the heterogeneity of risk factors in this population that could affect the rate of VTE such as minimal invasive (robotic) cystectomy or open radical cystectomy [10]. Additionally, 33 of the included studies did not state, discuss or categorise BC patients according to confounding factors that alter the rate of VTE such as receiving surgical thromboprophylaxis for 14 or 28 days, which then makes it difficult to compare rates between studies [13,[15][16][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53]. All included studies, with the exception of two [19][20], did not clearly discuss or state the thromboprophylaxis measures employed.…”

Section: Discussion Of the Systematic Reviewmentioning

confidence: 99%

Venous Thromboembolism Rate in Patients with Bladder Cancer According to the Type of Treatment: A systematic review

Abdullah¹,

Parashar²,

Mustafa³

et al. 2021

J Clin Oncol Ther

0

View full text Add to dashboard Cite

Bladder cancer (BC) is classified as a high-risk tumour type for venous thromboembolism (VTE). VTE presents an extra challenge in the management of patients with cancer, given the increase in morbidity and mortality on having both conditions.To summarise the contemporary evidence on the VTE rate in patients with BC according to the stage, type of anti-cancer treatment and highlight VTE rate in the UK and other countries. A systematic review was carried out, and an electronic search for publications between January 2000 and November 2021 was done. Studies recording VTE in BC patients were included, whilst paediatric patients, case reports, studies reporting on a mix of arterial and venous thrombosis, studies reporting DVT or PE only and recorded hospitalised VTE only were excluded. The rate of VTE, country of origin, risk factors and thromboprophylaxis duration for VTE in BC patients were identified.A total of 38 papers met the search criteria. All publications were original research papers (cohort studies). The overall VTE rate in patients with BC was estimated at 1.9% to 4.7%. For those patients undergoing cystectomy, the VTE rate ranged from 3% to 17.6%; however, the VTE rate in the metastatic stage of BC patients ranged from 3.1% to 5.1%.The rates of VTE in BC patients are high, further increased by interventions such as surgery and chemotherapy. Thromboprophylaxis measures should be optimised. This review highlighted the fact that the VTE rate in BC varies between studies due to the heterogeneity of risk factors reported.

show abstract

“…Infection is the second most common perioperative complication, and prophylactic antibiotics are prescribed to reduce infection. Wound-related complications are more common in open cystectomy, and deep vein thrombosis (DVT) is a serious postoperative complication affecting up to 4.7% of patients [ 49,50 ] .…”

Section: Early Complicationsmentioning

confidence: 99%

Ninety Days complications rate in patients undergoing radical cystectomy with enhanced recovery protocol

Hasan,

AbdelRazek,

Elamir

et al. 2024

Int J Chem Biochem Sci

0

View full text Add to dashboard Cite

Bladder cancer is a carcinoma of the urothelial, or “umbrella,” cells that line the lumen of the urinary bladder. Technically, urothelial carcinoma includes tumors of the bladder, upper urinary tract (renal pelvis and ureters), and proximal urethra. Bladder cancer accounts for approximately 90% to 95% of urothelial carcinoma; bladder cancer comprises 75% pure urothelial carcinoma and 25% “variant” histology, adding complexity to the management of this disease. Bladder cancer can be categorized in several way, almost all bladder cancers originate in the urothelium, which is a 3- to 7-cell mucosal layer within the muscular bladder. Squamous cell carcinoma of the bladder can involve multiple sites; however, the lateral wall and trigone are more commonly involved by this tumor. All small cell carcinomas of the urinary system identified so far have been located in the urinary bladder, most commonly in the dome and vesical lateral wall. Radical cystectomy is a crucial surgical technique in managing MIBC, high-risk NMIBC, and treatment-refractory NMIBC. Despite a high perioperative mortality rate (5-10%), it now carries a 1-2% mortality rate due to improvements in surgical technique, intensive care medicine evolution, and antibiotic availability.

show abstract

Mp50-05 Identifying Practice Patterns for Thromboprophylaxis After Radical Cystectomy.

Cited by 3 publications

References 0 publications

Venous Thromboembolism Rate in Patients With Bladder Cancer According to the Type of Treatment: A Systematic Review

Venous Thromboembolism Rate in Patients With Bladder Cancer According to the Type of Treatment: A Systematic Review

Venous Thromboembolism Rate in Patients with Bladder Cancer According to the Type of Treatment: A systematic review

Ninety Days complications rate in patients undergoing radical cystectomy with enhanced recovery protocol

Contact Info

Product

Resources

About